New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
10:00 EDTABY, BSX, DWA, ELGX, LXU, EVAR, LGF, STJ, ZFGNOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Abengoa Yield (ABY) initiated with a Neutral at HSBC... Boston Scientific (BSX) initiated with a Neutral at Sterne Agee... DreamWorks Animation (DWA) initiated with a Market Perform at FBR Capital... Endologix (ELGX) initiated with an Outperform at Credit Suisse... LSB Industries (LXU) initiated with a Buy at Feltl... Lionsgate (LGF) initiated with an Outperform at FBR Capital... Lombard Medical (EVAR) initiated with an Outperform at Credit Suisse... St. Jude Medical (STJ) initiated with a Neutral at Sterne Agee... Zafgen (ZFGN) initiated with an Outperform at JMP Securities.
News For ABY;BSX;DWA;ELGX;LXU;EVAR;LGF;STJ;ZFGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 16, 2014
06:05 EDTEVARLombard Medical completes first applications of Aorfix in New Zealand
Lombard Medical completed the first two EVAR cases performed in New Zealand using its lead product, Aorfix, an endovascular stent graft for AAA repair. Aorfix is the first and only endovascular stent graft with global approvals for the treatment of patients with aortic neck angulations up to 90 degrees. Lombard Medical launched Aorfix in Japan in September.
October 15, 2014
08:37 EDTSTJSt. Jude Medical expects AF products revenue to accelerate in FY15
As the company look to FY15, aims to continue to accelerate its sales growth rate. Expects the acceleration to come from its men's heart failure monitor system and chronic pain business. Expects to grow sales faster in FY15 compared to FY14.
08:32 EDTSTJSt. Jude Medical sees YOY currency impact on sales $50M-$60M for Q4
Subscribe for More Information
07:34 EDTSTJSt. Jude Medical reports Q3 total CRM sales $688M
Subscribe for More Information
07:34 EDTSTJSt. Jude Medical narrows FY14 adjusted EPS view to $3.97-$3.99 from $3.96-$4.01
Subscribe for More Information
07:32 EDTSTJSt. Jude Medical sees Q4 adjusted EPS $1.02-$1.04, consensus $1.04
Subscribe for More Information
07:32 EDTSTJSt. Jude Medical Sees FY14 adjusted EPS $3.97-$3.99, consensus $3.98
Sees FY14 revenue $5.586B-$5.648B, consensus $5.69B.
07:31 EDTSTJSt. Jude Medical reports Q3 adjusted EPS 97c, consensus 96c
Reports Q3 revenue $1.37B, consensus $1.38B.
October 14, 2014
15:29 EDTSTJNotable companies reporting before tomorrow's open
Subscribe for More Information
06:06 EDTELGXDeerfield reports 6.7% passive stake in Endologix
October 13, 2014
07:25 EDTSTJEuropean Association of Cardiothoracic Surgery to hold annual meeting
28th EACTS Annual Meeting is being held in Milan, Italy on October 11-15.
October 9, 2014
07:12 EDTLGFLionsgate outlook has improved, says Stifel
Subscribe for More Information
06:11 EDTEVARLombard Medical's Aorfix stent graft adopted by VA medical centers
Lombard Medical's lead product, Aorfix, is now being used by leading surgeons at 5 US Department of Veterans Affairs medical centers.
October 8, 2014
20:03 EDTBSXBoston Scientific confirms FDA panel votes for WATCHMAN device
After reviewing updated data and analysis for the Boston Scientific Corporation WATCHMAN Left Atrial Appendage Closure Device, the FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee voted in favor of the Device. By a vote of 6 to 5, with 1 abstention, the panel concluded that the benefits of the WATCHMAN Device outweigh the potential risks. The panel voted that there is reasonable assurance that the device is safe, with a 12 yes to 0 no vote. On the question of reasonable assurance of effectiveness, the panel vote was unfavorable with a 6 yes to 7 no vote. The panel provided substantial input and guidance related to the proposed Indications for use and target patient population. There was widespread agreement among the panel members that the device provides a much needed alternative to long-term anticoagulation for some patients. While not bound by this vote, the FDA takes Advisory Panel comments and recommendations into account when reviewing the WATCHMAN Device application. The company is committed to working with the FDA to address the panel's comments.
18:42 EDTBSXBoston Scientific Watchman Device receives votes from FDA panel, Dow Jones says
The FDA Panel voted 6 to 5 that benefits of Boston Scientific's Watchman device outweigh the risks, Dow Jones reports. The panel voted 12 to 0 that the Watchman device is safe, and the panel voted 7 to 6 that the Watchman device is not effective, Dow Jones added.
13:27 EDTDWASoftBank no longer talking to DreamWorks, Buzzfeed reports
Subscribe for More Information
09:05 EDTLGFLionsgate partners with Doritos, Mazda and Whole Foods Market for new film
Lionsgate (LGF) announced that PepsiCo's (PEP) Doritos, Mazda and Whole Foods Market's (WFM) Whole Planet Foundation will partner with the studio for the film The Hunger Games: Mockingjay – Part 1 which opens in theaters worldwide on November 21.
07:24 EDTBSXFDA Circulatory Systems Devices Panel to hold a meeting
The Committee discusses, makes recommendations and votes on information related to the Pre-Market Approval Application regarding Boston Scientific’s WATCHMAN Left Atrial Appendage (LAA) Closure Technology in a meeting being held in Gaithersburg, Maryland on October 8 at 8 am. Webcast Link
October 7, 2014
09:03 EDTLGFLionsgate expands distribution deal with Miramax
Subscribe for More Information
October 6, 2014
11:13 EDTBSXWells sees 60%-70% chance of positive FDA panel for Boston Scientific
After the FDA posted the briefing documents for the Watchman advisory committee meeting scheduled for October 8, Wells Fargo says it still believes chances of a positive panel and FDA approval are 60%-70%. The firm views the panel's focus on the "totality of data" is a positive signal. It has an Outperform rating on Boston Scientific.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use